Literature DB >> 8085382

Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens.

E Konishi1, S Pincus, E Paoletti, R E Shope, P W Wason.   

Abstract

An avipox virus, canarypox (ALVAC), which is naturally host-range restricted, was used to construct recombinants encoding the Japanese encephalitis virus (JEV) prM, E and NS1 genes (vCP107) and prM and E genes (vCP140). Mice immunized with these recombinant viruses produced JEV neutralizing antibodies and were protected from lethal JEV challenge. Protection was also observed in mice immunized with a subunit vaccine candidate, consisting of extracellular particles (EPs; RNA-free subviral membrane vesicles containing prM/M and E proteins) derived from HeLa cell cultures infected with a JEV-vaccinia recombinant. Mice primed with vCP107 and boosted with EPs had higher antibody levels than mice immunized twice with EPs alone, although the levels were comparable to that obtained in mice immunized twice with the recombinant virus. Mice immunized with a mixture of recombinant virus (vCP107) plus EPs had neutralizing antibody titres higher than mice immunized with the recombinant virus or EPs alone.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8085382     DOI: 10.1016/0264-410x(94)90269-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes.

Authors:  E Konishi; M Yamaoka; I Kurane; P W Mason
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

2.  Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form.

Authors:  S L Allison; K Stadler; C W Mandl; C Kunz; F X Heinz
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

3.  The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes.

Authors:  E Konishi; M Yamaoka; I Kurane; K Takada; P W Mason
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

4.  Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions.

Authors:  J Schalich; S L Allison; K Stiasny; C W Mandl; C Kunz; F X Heinz
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

Review 5.  Preventive strategies for frequent outbreaks of Japanese encephalitis in Northern India.

Authors:  Vandana Saxena; Tapan N Dhole
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

Review 6.  Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

Authors:  Ravi A Madan; Philip M Arlen; Mahsa Mohebtash; James W Hodge; James L Gulley
Journal:  Expert Opin Investig Drugs       Date:  2009-07       Impact factor: 6.206

Review 7.  Development of a recombinant vaccine against Japanese encephalitis.

Authors:  Rupinderjeet Kaur; Sudhanshu Vrati
Journal:  J Neurovirol       Date:  2003-08       Impact factor: 2.643

Review 8.  Structures and mechanisms in flavivirus fusion.

Authors:  F X Heinz; S L Allison
Journal:  Adv Virus Res       Date:  2000       Impact factor: 9.937

9.  Japanese encephalitis-a pathological and clinical perspective.

Authors:  Debapriya Ghosh; Anirban Basu
Journal:  PLoS Negl Trop Dis       Date:  2009-09-29

Review 10.  Japanese encephalitis: the virus and vaccines.

Authors:  Sang-Im Yun; Young-Min Lee
Journal:  Hum Vaccin Immunother       Date:  2013-10-25       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.